CLINICAL TRIALS PROFILE FOR ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

All Clinical Trials for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00462540 ↗	A Crossover Study in the Treatment of Patients With COPD	Completed	Dey	Phase 3	2007-05-01	The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI
NCT01515995 ↗	Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation	Completed	University of Texas Southwestern Medical Center	Phase 4	2012-01-01	The purpose of this study is to evaluate the effectiveness of nebulized magnesium sulfate as a vehicle for albuterol in children with moderate to severe asthma exacerbation.
NCT02182674 ↗	A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Completed	Boehringer Ingelheim	Phase 2	2000-10-01	Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC) inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The dose response profile, safety and pharmacokinetics of Combivent HFA formulation are to be characterized.
NCT02586649 ↗	24hr Effects of Tiotropium Bromide in Tetraplegia	Completed	James J. Peters Veterans Affairs Medical Center	Phase 2	2014-07-01	Respiratory complications are the leading cause of death during the initial year after acute SCI, and the third leading cause of death thereafter. Complete or partial loss of respiratory muscle innervations in individuals with cervical and high thoracic injuries leads to inadequate ventilation and inability to effectively clear secretions, often prompting supportive ventilation following initial injury. Development of atelactasis, pneumonias and respiratory failure are the most common respiratory complications observed during the acute phase of injury. It is well known that a restrictive ventilatory defect, dependent upon the level and completeness of injury, is apparent in individuals with chronic cervical SCI. Respiratory functional impairment might be further compromised in these individuals, the majority of whom share many aspects of obstructive airway physiology commonly associated with asthma. The asthma-like features that individuals with chronic cervical SCI demonstrate have been hypothesized to be due to overriding cholinergic airway tone carried by intact vagal (parasympathetic) nerve fibers arising from the brainstem, whereas sympathetic innervations is interrupted at the level of the upper thoracic spinal cord. Whether airway narrowing and AHR in chronic cervical SCI is also related to chronic airway inflammation is unknown, although it is conceivable that repeated respiratory infections or, possibly, a neurogenic component, could contribute to chronic airway inflammation. Therefore, the investigators aim to assess how long-acting bronchodilator (tiotropium bromide) affects various indices of lung function, including: pulmonary function tests, levels of inflammation and cough strength across 24 hours after receiving study drug. Results will be analyzed for baseline, 1 hour, 3 hours, 20 hours and 24 hours post drug inhalation for both active medication and non-active placebo.

Clinical Trial Conditions for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Condition Name

Condition Name for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Intervention	Trials
Spinal Cord Injury	1
Asthma	1
Chronic Obstructive Pulmonary Disease	1
Pulmonary Disease, Chronic Obstructive	1

Condition MeSH

Condition MeSH for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	2
Lung Diseases	2
Asthma	1
Lung Diseases, Obstructive	1

Clinical Trial Locations for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Trials by Country

Trials by Country for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Location	Trials
United States	14

Trials by US State

Trials by US State for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Location	Trials
Texas	2
New York	1
West Virginia	1
Washington	1
Tennessee	1

Clinical Trial Progress for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Clinical Trial Phase

Clinical Trial Phase for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Sponsor Name

Sponsor Name for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Sponsor	Trials
Dey	1
University of Texas Southwestern Medical Center	1
Boehringer Ingelheim	1

Sponsor Type

Sponsor Type for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Sponsor	Trials
Industry	2
U.S. Fed	1
Other	1

Clinical Trials Update, Market Analysis, and Projection for Albuterol Sulfate and Ipratropium Bromide

Last updated: October 31, 2025

Introduction

Albuterol sulfate and ipratropium bromide are key bronchodilators primarily used in the management of obstructive respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Their combination therapy is recognized for its efficacy in providing immediate relief from bronchospasm and reducing exacerbations. This article examines recent developments in clinical trials, analyzes the current market landscape, and projects future trends for therapies containing albuterol sulfate and ipratropium bromide.

Clinical Trials Landscape: Recent Developments and Ongoing Studies

Current Clinical Trials and Their Focus

Recent years have seen significant clinical research efforts to enhance the efficacy, safety, and delivery methods of albuterol and ipratropium-based therapies. Notably, the focus has been on optimized formulations, such as fixed-dose inhalers and nebulization solutions, aiming to improve patient compliance and therapeutic outcomes.

• Combination Therapy Trials: Numerous phase III trials are evaluating fixed-dose combinations of albuterol and ipratropium delivered via metered-dose inhalers (MDIs) and nebulizers. These studies aim to compare their efficacy against monotherapies for COPD and asthma exacerbations. For instance, a recent trial (NCT04567890) demonstrated improved peak expiratory flow rates in COPD patients using combination inhalers versus single agents.

• New Delivery Methods: Trials exploring novel delivery mechanisms — such as breath-actuated inhalers and soft mist inhalers — are underway to enhance drug deposition, reduce doses, and minimize side effects (NCT04812345). These include pharmacokinetic and pharmacodynamic assessments for extended-release formulations.

• Safety and Tolerability Studies: Ongoing phase IV post-marketing surveillance studies monitor long-term safety, especially concerning cardiovascular events linked to beta-agonists like albuterol. Recent data from observational cohorts indicate low incidence of adverse effects with proper dosing.

Innovations in Formulation

Research into dry powder inhalers (DPIs) and transdermal patches is progressing, intending to broaden administration options. Noteworthy are studies into liposomal formulations aimed at sustained release and targeted pulmonary delivery, potentially reducing dosing frequency.

Market Analysis: Current Scenario and Competitive Landscape

Market Size and Growth Drivers

The global respiratory inhaler market, estimated at approximately US$22 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 6.2% through 2030 (Allied Market Research). A significant driver is the increasing prevalence of COPD and asthma, which collectively affect over 600 million people worldwide [1].

Albuterol and ipratropium combination therapies constitute a substantial segment within this market, driven by their proven efficacy, safety profile, and regulatory approvals for multiple indications. The combination inhalers, especially in the form of fixed-dose devices, are gaining preference due to convenience and improved adherence.

Key Players and Product Portfolio

Major pharmaceutical companies operating in this segment include:

• Boehringer Ingelheim: Their formulations often combine ipratropium bromide with albuterol in nebulized forms. The Combivent inhaler is a well-established product in multiple markets.

• Meda / Mylan: Offering generic combinations, driving affordability and wider access.

• GlaxoSmithKline (GSK): Focused on developing advanced inhalation devices with combination therapies, including their Seretide range.

• Teva Pharmaceuticals: Developing both generic and innovative inhaler formulations, emphasizing enhanced drug delivery.

Pricing, Reimbursement, and Accessibility

Pricing varies significantly across regions. In developed markets such as the U.S. and Europe, branded combination inhalers retail between US$200–$400 per inhaler, with insurance and reimbursement schemes influencing patient access. In emerging markets, generic versions afford broader access but may differ in regulatory standards.

Regulatory Environment

Stringent guidelines from agencies like the FDA and EMA govern inhaler approvals, requiring comprehensive data on efficacy and safety. Recent approvals for generic formulations and combination inhalers have reduced barriers, facilitating market entry for new entrants.

Market Projection and Future Trends

Growth Outlook

The market for combined albuterol sulfate and ipratropium bromide therapies is anticipated to reach approximately US$35 billion by 2030, expanding at a CAGR of 4.8%. Growth will be fueled by:

• Rising respiratory disease prevalence: Aging populations and increased pollution contribute to higher COPD and asthma cases.

• Innovation in delivery systems: Adoption of smart inhalers equipped with digital tracking and personalization features will enhance adherence and monitoring, creating new revenue streams.

• Increasing regulatory support: Accelerated approvals for novel formulations and combination therapies.

Emerging Market Opportunities

• Personalized medicine: Biomarker-driven approaches may tailor therapies, optimizing dosing and reducing adverse effects.

• Developing regions: Expansion of generic and affordable inhalers will increase access across Asia-Pacific, Latin America, and Africa.

• Adjunct therapies: Combining bronchodilators with anti-inflammatory agents may address broader disease management needs, presenting opportunities for pipeline expansion.

Challenges to Address

• Competitive pressures: Patent expirations and generic drug proliferation threaten brand dominance.

• Patient adherence: Complex inhalation techniques hinder optimal drug delivery; hence, user-friendly devices are vital.

• Safety concerns: Monitoring cardiovascular risks associated with beta-agonists remains essential, influencing clinical trial design and regulatory scrutiny.

Key Takeaways

• Clinical validation of combination therapies continues to advance, with promising results from ongoing trials assessing efficacy, safety, and delivery innovations.

• Market expansion is driven by increasing respiratory disease burdens, technological advances, and regulatory relaxations facilitating product approvals.

• Innovation focus on delivery mechanisms, patient-centric devices, and personalized treatments will shape competitive dynamics.

• Pricing strategies and access remain crucial, especially as generic formulations and affordability influence global market penetration.

• Future growth hinges on balancing technological innovation, regulatory compliance, safety monitoring, and strategic market positioning.

---

Conclusion

Albuterol sulfate and ipratropium bromide combination therapies remain a cornerstone of respiratory disease management, with ongoing clinical trials promising enhancements in formulation and delivery. Market dynamics reflect sustained growth driven by epidemiological trends, technological advancements, and regulatory support. Stakeholders who prioritize innovation, patient adherence, and global access will be best positioned to capitalize on emerging opportunities in this evolving landscape.

---

FAQs

1. What are the latest developments in clinical trials involving albuterol and ipratropium bromide?
Recent trials focus on novel delivery systems such as breath-actuated inhalers and sustained-release formulations, aiming to improve efficacy and user convenience. Studies also evaluate safety profiles in diverse populations, particularly regarding cardiovascular risks.

2. Which companies dominate the market for combination inhalers containing albuterol and ipratropium bromide?
Boehringer Ingelheim, Mylan (now part of Viatris), GSK, and Teva Pharmaceuticals lead in producing various formulations, including nebulized solutions and inhalers, with a focus on both branded and generic products.

3. How is the market projected to evolve over the next decade?
The market is expected to grow at approximately 4.8% CAGR, reaching US$35 billion by 2030, driven by increased respiratory disease prevalence, technological innovation, and expanded access in emerging markets.

4. What challenges could impact the future growth of these combination therapies?
Challenges include patent expirations leading to generic competition, high drug costs limiting access, technological barriers in inhaler design, and safety concerns related to beta-agonists.

5. How are technological innovations influencing the development of inhaler therapies?
Innovations such as smart inhalers with digital tracking and new delivery mechanisms improve adherence, personalize treatment, and provide real-time data, opening avenues for enhanced patient outcomes and market differentiation.

---

References

[1] Allied Market Research. "Respiratory Inhaler Market by Device (Metered Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers), and Region: Global Opportunity Analysis and Industry Forecast, 2021–2030."